CCSG Developmental Funds are critical to the continued growth and development of the Winship Cancer Institute (Winship). These funds provide a critical base of funding enabling Winship to advance its strategic plan by investing in the cancer center's highest priorities. Winship's initial type 1 CCSG award Included approximately $800,000 of Development Funds over three years, and these funds have supported Winship's pilot grant program and two developing shared resources, Bioinfonnatics and Transgenic Mouse Facility. Since April 2009, Winship has distributed 24 pilot grants directly linked to CCSG developmental funds. In addition, the Winship has allocated over $1 million in philanthropic funds for matching pilot grants during the same time period. In total, Winship has distributed over $1.4 million in pilot grant funding to its members to accelerate progress within their research programs, in this current application, Winship is requesting $437,818 in developmental funds per year primarily to continue its pilot grant program and to advance Winship's strategic initiatives through faculty recruitment. This would be allocated as $200,000/year for faculty recruitment in defined domains as identified by the Winship Strategic Plan 2010-2015. Another $200,000/year would continue to support the Winship Pilot Grant Program, with a particular focus on awards that Involve: 1. New Investigations in partnership with the Emory Chemical Biology Center;2. New initiatives in comparative effectiveness research In oncology;3. Research projects in conjunction with an NCI-supported cancer cooperative group or network;4. Research partnerships with investigators from another NCI-designated cancer center;or 5. Investigations in partnership with faculty from another research institution in Georgia. The current request for Developmental Funds in combination with the continued commitment of institutional funds will allow the Executive Director and his leadership team to continue the planned development in a number of strategic recruitments and research development. This support will enable Winship to move toward fulfilling its vision of being a transformative leader in the integration of cancer research, education, and care.
The requested Developmental Funds will provide additional support for the continued growth and development by sponsoring faculty recruitment and pilot grants for the members of the Winship Cancer Institute.
|Richardson, Alessandra M; Havel, Lauren S; Koyen, Allyson E et al. (2018) Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion. Clin Cancer Res 24:420-432|
|Goldstein, Jordan S; Nastoupil, Loretta J; Han, Xuesong et al. (2018) Disparities in survival by insurance status in follicular lymphoma. Blood 132:1159-1166|
|Guidot, Daniel M; Switchenko, Jeffrey M; Nastoupil, Loretta J et al. (2018) Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk Lymphoma 59:888-895|
|Jin, Lingtao; Chun, Jaemoo; Pan, Chaoyun et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell 34:315-330.e7|
|Chowdhary, Mudit; Okwan-Duodu, Derick; Switchenko, Jeffrey M et al. (2018) Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. J Neurooncol 136:289-298|
|Chen, Zhengjia; Zheng, Youyun; Wang, Zhibo et al. (2018) Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs. Contemp Clin Trials Commun 12:145-153|
|Halani, Sameer H; Yousefi, Safoora; Vega, Jose Velazquez et al. (2018) Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. NPJ Precis Oncol 2:24|
|Ferris, Matthew J; Liu, Yuan; Ao, Jingning et al. (2018) The addition of chemotherapy in the definitive management of high risk prostate cancer. Urol Oncol 36:475-487|
|Halicek, Martin; Little, James V; Wang, Xu et al. (2018) Deformable Registration of Histological Cancer Margins to Gross Hyperspectral Images using Demons. Proc SPIE Int Soc Opt Eng 10581:|
|Cassidy, Richard J; Switchenko, Jeffrey M; El-Deiry, Mark W et al. (2018) Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas. Laryngoscope :|
Showing the most recent 10 out of 331 publications